PETACH TIKVA, Israel,
May 18, 2016 /PRNewswire/ --
Emerald Medical Applications Corp. (OTCQB: MRLA) ("Emerald" or
the "Company"), the Israeli-based company engaged in the
development and sale of DermaCompare™, its proprietary artificial
intelligence technology and application for the early diagnosis of
melanoma and other skin cancers, today announced that
Dr. Ben-Zion Weiner has joined the Company's Scientific
Advisory Board.
From 1975 to 2012, Dr. Weiner held executive positions with Teva
Pharmaceutical Industries Ltd (NYSE: TEVA) and its
subsidiaries ("Teva"). He was Vice President of Global Products of
Teva from 2005 to 2011 where he was responsible for global
Generic and Innovative Research and Development.
Dr. Weiner was also a Member of the Core Management
Committee.
Dr. Weiner holds a B.Sc. Degree in General Chemistry and
Biochemistry, graduating with distinction at the Hebrew
University, Jerusalem, a M.Sc.
Degree in Organic Chemistry, graduating with distinction at
the Hebrew University of Jerusalem, and a Ph.D. Degree from
the Hebrew University, Jerusalem. Dr. Weiner did his Post-Doctorate
studies at Schering Plough Corporation in Bloomfield,
New Jersey, on "Exploratory work
of new drugs, research in organic chemistry, and pharmacology." Dr.
Weiner received twice the Rothschild Prize for Innovation/Export
for the development of Copaxone(R) for Multiple Sclerosis and for
the development of alpha D3 for Dialysis and
Osteoporosis.
Dr. Weiner commented, "I am pleased with the high potential
of Emerald's DermaCompare™ technology. My pharmaceutical
background will allow me to consult and advise the company on how
to maximize current and future applications for the technology. Dr.
Weiner went on saying: "I am honored and privileged to join forces
with Professor Perry Robbins
and Lior Wayn, CEO of Emerald Medical Applications Corp.,
stated, "I would like to officially welcome Dr. Weiner to our
Scientific advisory board. His qualifications and expertise in the
areas of chemistry, pharmacology and pharmaceutical products will
undoubtedly be of significant value as we explore to
maximize our DermaCompare's potential. I believe that our ability
to combine the power of artificial intelligence with the utility of
a mobile app will revolutionize the way we detect and diagnose
melanoma and, in the future, other skin conditions.
About Emerald Medical Applications Corp
Emerald Medical Applications is an Israeli-based medical
technology company that utilizes proprietary military image
processing technology and state of the art data analytics to
improve the analysis of medical images. Emerald's flagship
solution, DermaCompare™, is an FDA Class #1 approved,
HIPPA-compliant, skin cancer (melanoma) screening platform that
enables physicians to identify and monitor changes in their
patients' skin health, specifically the early detection of
cancerous moles and skin anomalies.
The DermaCompare™ patient application is available in Mac or
Android based platforms and works using virtually any digital
camera, including cell phones, iPads, tablets and other similar
devices, to take Total Body Photography ("TBP") images and, in
real-time, transmit these images for dermatological evaluation and
identification of suspicious moles, lesions and other skin
conditions. These images are then compared using Emerald's cloud
database, as well as the patient's previous Total Body Photography
images, which will dramatically enhance a physician's ability to
detect Melanoma earlier, more accurately and more efficiently than
other means of diagnosis.
For more information,
visit: http://www.dermacompare.com/
Notice Regarding Forward-Looking Statements
This press release may contain forward-looking statements, about
Emerald's expectations, beliefs or intentions regarding, among
other things, its product development efforts, business, financial
condition, results of operations, strategies or prospects. In
addition, from time to time, Emerald or its representatives
have made or may make forward-looking statements, orally or in
writing. Forward-looking statements can be identified by the use of
forward-looking words such as "believe," "expect," "intend,"
"plan," "may," "should" or "anticipate" or their negatives or other
variations of these words or other comparable words or by the fact
that these statements do not relate strictly to historical or
current matters. These forward-looking statements may be included
in, but are not limited to, various filings made by Emerald with
the U.S. Securities and Exchange Commission, press releases or oral
statements made by or with the approval of one of Emerald's
authorized executive officers. Forward-looking statements relate to
anticipated or expected events, activities, trends or results as of
the date they are made. Because forward-looking statements relate
to matters that have not yet occurred, these statements are
inherently subject to risks and uncertainties that could cause
Emerald's actual results to differ materially from any future
results expressed or implied by the forward-looking statements.
Many factors could cause Emerald's actual activities or results to
differ materially from the activities and results anticipated in
such forward-looking statements, including, but not limited to, the
factors summarized in Emerald's filings with the SEC. In addition,
Emerald operates in an industry sector where securities values are
highly volatile and may be influenced by economic and other factors
beyond its control. Emerald does not undertake any obligation to
publicly update these forward-looking statements, whether as a
result of new information, future events or otherwise. Reference is
made to the disclosure under "risk factors" included in our
Registration Statement on Form S-1 which was declared effective by
the U.S. Securities and Exchange Commission on January 20, 2016.
Contact:
Lior Wayn, CEO
+1-917-7242059
+972-50-6816300
ir@dermacompare.com
SOURCE Emerald Medical Applications Corp.